CompletedPhase 1ketamine

Ketamine Trial for the Treatment of Depression

NCT ID

NCT02401139

Target Enrollment

10 participants

Start Date

2015-03

Est. Completion

2015-09

About This Study

This study is a Randomized Controlled Trial, investigating the safety and efficacy of administration of ketamine as a potential treatment for depression.

Conditions Studied

Unipolar Depression

Interventions

•Ketamine
•Placebo

Eligibility

Age:16 Years - N/A

Healthy Volunteers:No

View full eligibility criteria

Individuals will be eligible for enrolment on the basis of:

* major depressive disorder for at least three months duration
* an inadequate response to at least 2 adequate antidepressants
* MADRS ≥ 20

Patients will be excluded on the basis of:

* History of psychosis
* History of bipolar disorder
* Any unstable medical or neurologic condition
* Any Axis I disorder other than MDD judged to be primary presenting problem
* Planned major changes to psychotropic medication
* Significant risk of suicide
* Planned or probable use of ECT
* Age under 16 years, or 16-17 years without parental consent
* Substance abuse or dependence in previous 6 months
* Any history of abuse of ketamine or phencyclidine
* Contraindication to the use of ketamine
* Planned use of ketamine
* Women of childbearing potential not taking reliable contraception
* Likely non-compliance with trial treatment
* Other condition judged by the treating clinician as likely to impact on the ability of the participant to complete the trial

Study Locations (2)

Brain & Mind Research Institute (BMRI), University of Sydney

Camperdown, New South Wales, Australia

Black Dog Institute, University of New South Wales